Identification

Name
Hydroxychloroquine
Accession Number
DB01611
Type
Small Molecule
Groups
Approved
Description

Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer.2 Hydroxychloroquine is an aminoquinoline like chloroquine.13 It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus.13 Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely.13 It was developed during World War II as a derivative of quinacrine with less severe side effects.6 Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.7

The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.14

Hydroxychloroquine was granted FDA approval on 18 April 1955.13

A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.10

Structure
Thumb
Synonyms
  • (±)-hydroxychloroquine
  • 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
  • 2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
  • 7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
  • 7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
  • 7-chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
  • 7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
  • Hidroxicloroquina
  • Hydroxychloroquine
  • Hydroxychloroquinum
  • Oxichlorochine
  • Oxichloroquine
Product Ingredients
IngredientUNIICASInChI Key
Hydroxychloroquine sulfate8Q2869CNVH747-36-4JCBIVZZPXRZKTI-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PlaquenilTablet200 mg/1OralAphena Pharma Solutions Tennessee, Inc.2013-06-28Not applicableUs
PlaquenilTablet200 mg/1OralCarilion Materials Management2013-06-28Not applicableUs
PlaquenilTabletOralSanofi Aventis1957-12-31Not applicableCanada
PlaquenilTablet200 mg/1OralRedPharm Drug, Inc.2020-01-01Not applicableUs
PlaquenilTablet200 mg/1OralProficient Rx LP2013-06-28Not applicableUs
PlaquenilTablet200 mg/1OralConcordia Pharmaceuticals Inc.2013-06-28Not applicableUs
PlaquenilTablet200 mg/1OralAvKARE, Inc.2016-07-142019-03-31Us
PlaquenilTablet, film coated200 mg/1OralSanofi Aventis1955-04-182013-05-31Us
PlaquenilTablet200 mg/1OralCovis Pharmaceuticals, Inc.2013-06-282017-12-31Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-hydroxyquineTabletOralApotex Corporation2002-12-13Not applicableCanada
Hydroxychloroquine SulfateTablet, film coated200 mg/1OralHikma Pharmaceuticals USA Inc.2007-08-152014-01-31Us
Hydroxychloroquine SulfateTablet, film coated200 mg/1OralA-S Medication Solutions2016-03-30Not applicableUs
Hydroxychloroquine SulfateTablet, film coated200 mg/1OralPhysicians Total Care, Inc.1996-07-09Not applicableUs
Hydroxychloroquine SulfateTablet, film coated200 mg/1OralDoh Central Pharmacy2017-08-27Not applicableUs
Hydroxychloroquine SulfateTablet, film coated200 mg/1OralAmneal Pharmaceuticals NY LLC2018-05-17Not applicableUs
Hydroxychloroquine sulfateTablet, film coated200 mg/1OralCadila Healthcare Limited2008-01-03Not applicableUs
Hydroxychloroquine SulfateTablet200 mg/1OralRemedy Repack2011-04-132011-04-14Us
Hydroxychloroquine SulfateTablet, film coated200 mg/1OralRebel Distributors2009-01-07Not applicableUs
Hydroxychloroquine SulfateTablet, film coated200 mg/1OralMajor Pharmaceuticals1995-11-302019-11-30Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
International/Other Brands
Dolquine (Inmunosyn) / HCQS (Medigroup) / Polirreumin (TRB) / Quensyl (Sanofi)
Categories
UNII
4QWG6N8QKH
CAS number
118-42-3
Weight
Average: 335.872
Monoisotopic: 335.176440176
Chemical Formula
C18H26ClN3O
InChI Key
XXSMGPRMXLTPCZ-UHFFFAOYSA-N
InChI
InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
IUPAC Name
2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol
SMILES
CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1

Pharmacology

Indication

Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.13

Associated Conditions
Pharmacodynamics

Hydroxychloroquine affects the function of lysozomes in humans as well as plasmodia.4 Altering the pH of the lysozomes reduces low affinity self antigen presentation in autoimmue diseases and interferes with the ability of plasmodia to proteolyse hemoglobin for their energy requirements.4 Hydroxychloroquine has a long duration of action as it may be taken on a weekly basis for some indications.13 Hydroxychloroquine may lead to severe hypoglycemia and so diabetic patients are advised to monitor their blood glucose levels.13 Hydroxychloroquine is not effective against malaria in areas where chloroquine resistance has been reported.13

Mechanism of action

The exact mechanisms of hydroxychloroquine are unknown. It has been shown that hydroxychloroquine accumulates in the lysosomes of the malaria parasite, raising the pH of the vacuole.4 This activity interferes with the parasite's ability to proteolyse hemoglobin, preventing the normal growth and replication of the parasite.4 Hydroxychloroquine can also interfere with the action of parasitic heme polymerase, allowing for the accumulation of the toxic product beta-hematin.5

Hydroxychloroquine accumulation in human organelles also raise their pH, which inhibits antigen processing, prevents the alpha and beta chains of the major histocompatibility complex (MHC) class II from dimerizing, inhibits antigen presentation of the cell, and reduces the inflammatory response.4 Elevated pH in the vesicles may alter the recycling of MHC complexes so that only the high affinity complexes are presented on the cell surface.4 Self peptides bind to MHC complexes with low affinity and so they will be less likely to be presented to autoimmune T cells.4 Hydroxychloroquine also reduces the release of cytokines like interleukin-1 and tumor necrosis factor, possibly through inhibition of Toll-like receptors.4,11

The raised pH in endosomes, prevent virus particles (such as SARS-CoV and SARS-CoV-2) from utilizing their activity for fusion and entry into the cell.8

Hydroxychloroquine inhibits terminal glycosylation of ACE2, the receptor that SARS-CoV and SARS-CoV-2 target for cell entry.9,8 ACE2 that is not in the glycosylated state may less efficiently interact with the SARS-CoV-2 spike protein, further inhibiting viral entry.8

TargetActionsOrganism
ADNA
cross-linking/alkylation
Humans
AToll-like receptor 7
antagonist
Humans
AToll-like receptor 9
antagonist
Humans
UAngiotensin-converting enzyme 2
modulator
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Hydroxychloroquine is 67-74% bioavailable.2 Bioavailability of the R and S enantiomers were not significantly different.2 Following a 200mg oral dose, hydroxychloroquine reached a Cmax of 129.6ng/mL with a Tmax of 3.26h in the blood and a Cmax of 50.3ng/mL with a Tmax of 3.74h in the plasma.13 Following 155mg and 310mg intravenous doses, Cmax in the blood ranged from 1161-2436ng/mL with an average of 1918ng/mL.13

Volume of distribution

Hydroxychloroquine has a volume of distribution of 5522L from blood and 44,257L from plasma.2

Protein binding

The S enantiomer of hydroxychloroquine is 64% protein bound in plasma.2 It is 50% bound to serum albumin and 29% bound to alpha-1-acid glycoprotein.2 The R enantiomer is 37% protein bound in plasma.2 It is 29% bound to serum albumin and 41% bound to alpha-1-acid glycoprotein.2 In total, hydroxychloroquine is 50% protein bound in plasma.2

Metabolism

Hydroxychloroquine is N-dealkylated by CYP3A4 to the active metabolite desethylhydroxychloroquine, as well as the inactive metabolites desethylchloroquine and bidesethylchloroquine.1,3 Desethylhydroxychloroquine is the major metabolite.13

Route of elimination

40-50% of hydroxychloroquine is excreted renally, while only 16-21% of a dose is excreted in the urine as unchanged drug.2 5% of a dose is sloughed off in skin and 24-25% is eliminated through the feces.12

Half life

Oral hydroxychloroquine has an absorption half life of 3-4 hours.2,13 A 200mg oral dose of hydroxychloroquine has a half life of 537 hours or 22.4 days in blood, and 2963 hours or 123.5 days in plasma.13 A 155mg intravenous dose has a half life of 40 days.13

Clearance

The clearance of hydroxychloroquine is 96mL/min.2

Toxicity

Patients experiencing an overdose may present with headache, drowsiness, visual disturbances, cardiovascular collapse, convulsions, hypokalemia, rhythm and conduction disorders including QT prolongation, torsades de pointes, ventricular tachycardia, and ventricular fibrillation.13 This may progress to sudden respiratory and cardiac arrest.13 Overdose should be treated with immediate gastric lavage and activated charcoal at a dose of at least 5 times the hydroxychloroquine dose within 30 minutes.2,13 Parenteral diazepam may be given to treat cardiotoxicity, transfusion may reduce serum concentrations of drug, patients should be monitored for at least 6 hours, fluids should be given, and ammonium chloride should be given to acidify urine and promote urinary excretion.13 Patients may also be given epinephrine.11

Affected organisms
  • Plasmodium
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with 2-Methoxyethanol.
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Hydroxychloroquine.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Hydroxychloroquine.
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Hydroxychloroquine.
7-NitroindazoleThe therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Hydroxychloroquine.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Hydroxychloroquine.
AbetimusThe risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Abetimus.
AbexinostatThe risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Abexinostat.
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Hydroxychloroquine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take with food. Take with a meal or glass of milk.

References

Synthesis Reference

U.S. Patent 2,546,658.

General References
  1. Lim HS, Im JS, Cho JY, Bae KS, Klein TA, Yeom JS, Kim TS, Choi JS, Jang IJ, Park JW: Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75. doi: 10.1128/AAC.00339-08. Epub 2009 Feb 2. [PubMed:19188392]
  2. Furst DE: Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996 Jun;5 Suppl 1:S11-5. [PubMed:8803904]
  3. Collins KP, Jackson KM, Gustafson DL: Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. J Pharmacol Exp Ther. 2018 Jun;365(3):447-459. doi: 10.1124/jpet.117.245639. Epub 2018 Feb 8. [PubMed:29438998]
  4. Fox RI: Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993 Oct;23(2 Suppl 1):82-91. [PubMed:8278823]
  5. Chou AC, Fitch CD: Heme polymerase: modulation by chloroquine treatment of a rodent malaria. Life Sci. 1992;51(26):2073-8. doi: 10.1016/0024-3205(92)90158-l. [PubMed:1474861]
  6. Shippey EA, Wagler VD, Collamer AN: Hydroxychloroquine: An old drug with new relevance. Cleve Clin J Med. 2018 Jun;85(6):459-467. doi: 10.3949/ccjm.85a.17034. [PubMed:29883308]
  7. Devaux CA, Rolain JM, Colson P, Raoult D: New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 Mar 11:105938. doi: 10.1016/j.ijantimicag.2020.105938. [PubMed:32171740]
  8. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2:69. doi: 10.1186/1743-422X-2-69. [PubMed:16115318]
  9. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4. [PubMed:32020029]
  10. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P, Raoult D: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949. doi: 10.1016/j.ijantimicag.2020.105949. [PubMed:32205204]
  11. Chary MA, Barbuto AF, Izadmehr S, Hayes BD, Burns MM: COVID-19: Therapeutics and Their Toxicities. J Med Toxicol. 2020 Apr 30. pii: 10.1007/s13181-020-00777-5. doi: 10.1007/s13181-020-00777-5. [PubMed:32356252]
  12. Browning, David J. (2014). Hydroxychloroquine and chloroquine retinopathy. Springer. [ISBN:9781493905973]
  13. FDA Approved Drug Products: Hydroxychloroquine Oral Tablets [Link]
  14. FDA: Emergency use Authorization for Hydroxychloroquine and Chloroquine Revoked [Link]
External Links
Human Metabolome Database
HMDB0015549
KEGG Drug
D08050
KEGG Compound
C07043
PubChem Compound
3652
PubChem Substance
46508459
ChemSpider
3526
RxNav
5521
ChEBI
5801
ChEMBL
CHEMBL1535
Therapeutic Targets Database
DAP000878
PharmGKB
PA164777036
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Hydroxychloroquine
ATC Codes
P01BA02 — Hydroxychloroquine
AHFS Codes
  • 08:30.08 — Antimalarials

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedSupportive CareLiver Cirrhosis / Muscle Cramps1
0CompletedTreatmentMalignant Melanoma of Skin / Melanoma (Skin)1
0CompletedTreatmentPlasma Cell Myeloma1
0Enrolling by InvitationPreventionAntimalarials / Antirheumatic Agents / Enzyme Inhibitors / Hydroxychloroquine / Novel Coronavirus Infectious Disease (COVID-19)1
0SuspendedTreatmentNovel Coronavirus Infectious Disease (COVID-19)2
0TerminatedTreatmentProstate Cancer1
0WithdrawnTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
1Active Not RecruitingTreatmentAdult Solid Neoplasm1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Stage III Cutaneous Melanoma AJCC v7 / Stage III Prostate Cancer AJCC v7 / Stage III Renal Cell Cancer AJCC v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Prostate Cancer AJCC v7 / Stage IV Renal Cell Cancer AJCC V71
1Active Not RecruitingTreatmentMalignant Solid Tumours1
1CompletedTreatmentCystic Fibrosis (CF)1
1CompletedTreatmentImmunosuppression / Rheumatism1
1CompletedTreatmentLymphangioleiomyomatosis1
1CompletedTreatmentMelanoma1
1CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1CompletedTreatmentRefractory or Relapsed Solid Tumors1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1Not Yet RecruitingTreatmentAdvanced Breast Cancer / Tumors, Solid1
1RecruitingTreatmentKRAS Gene Mutation / Pancreatic Adenocarcinoma Metastatic / Stage IV Pancreatic Cancer AJCC v81
1RecruitingTreatmentMetastatic Pancreatic Carcinoma / Stage II Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Unresectable Pancreatic Carcinoma1
1RecruitingTreatmentMultiple Myeloma (MM)1
1RecruitingTreatmentNeoplasms, Gastrointestinal1
1RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
1RecruitingTreatmentTumors, Solid1
1SuspendedTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
1TerminatedTreatmentAcute Myeloid Leukemia (AML)1
1TerminatedTreatmentBone Metastases / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentEstrogen Receptor Positive Breast Cancer1
1TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1TerminatedTreatmentRenal Cell Adenocarcinoma1
1Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2Active Not RecruitingTreatmentAdvanced Adenocarcinoma / Metastatic Adenocarcinoma1
1, 2Active Not RecruitingTreatmentAdvanced BRAF Mutant Melanoma1
1, 2Active Not RecruitingTreatmentPlatinum-resistant Epithelial Ovarian Cancer1
1, 2CompletedDiagnosticSystemic Lupus Erythematosus (SLE)1
1, 2CompletedTreatmentAcne Inversa / Follicular Occlusion Tetrad / Follicular Occlusion Triad / Furuncle / Hidradenitis / Hidradenitis Suppurativa (HS)1
1, 2CompletedTreatmentAcute HIV Infection1
1, 2CompletedTreatmentAdenocarcinomas / Malignant Neoplasm of Colon / Metastasis / Rectal Carcinoma1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedTreatmentMalignant Neoplasm of Pancreas1
1, 2CompletedTreatmentMetastatic Clear Cell Renal Cell Carcinoma1
1, 2CompletedTreatmentMetastatic Renal Cell Carcinoma1
1, 2Not Yet RecruitingTreatmentGastrointestinal Cancers1
1, 2Not Yet RecruitingTreatmentMyelodysplastic Syndromes (MDS) / Progressive Disease1
1, 2Not Yet RecruitingTreatmentType 2 Diabetes Mellitus1
1, 2RecruitingPreventionNovel Coronavirus Infectious Disease (COVID-19)1
1, 2RecruitingTreatmentAnatomic Stage I Breast Cancer AJCC v8 / Anatomic Stage IA Breast Cancer AJCC v8 / Anatomic Stage IB Breast Cancer AJCC v8 / Anatomic Stage II Breast Cancer AJCC v8 / Anatomic Stage IIA Breast Cancer AJCC v8 / Anatomic Stage IIB Breast Cancer AJCC v8 / Anatomic Stage III Breast Cancer AJCC v8 / Anatomic Stage IIIA Breast Cancer AJCC v8 / Anatomic Stage IIIB Breast Cancer AJCC v8 / Anatomic Stage IIIC Breast Cancer AJCC v8 / Anatomic Stage IV Breast Cancer AJCC v8 / Estrogen Receptor Positive / HER2/Neu Negative / MKI67 Positive / One to five years postmenopausal / Prognostic Stage I Breast Cancer AJCC v8 / Prognostic Stage IA Breast Cancer AJCC v8 / Prognostic Stage IB Breast Cancer AJCC v8 / Prognostic Stage IIA Breast Cancer AJCC v8 / Prognostic Stage IIB Breast Cancer AJCC v8 / Prognostic Stage III Breast Cancer AJCC v8 / Prognostic Stage IIIA Breast Cancer AJCC v8 / Prognostic Stage IIIB Breast Cancer AJCC v8 / Prognostic Stage IIIC Breast Cancer AJCC v8 / Prognostic Stage IV Breast Cancer AJCC v81
1, 2RecruitingTreatmentDisseminated Sclerosis1
1, 2RecruitingTreatmentHigh Grade Glioma (HGG) of the Brain With BRAF Aberration / Low Grade Glioma (LGG) of Brain With BRAF Aberration / Low Grade Glioma of Brain With Neurofibromatosis Type 11
1, 2RecruitingTreatmentMelanoma1
1, 2RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
1, 2RecruitingTreatmentProstate Cancer1
1, 2RecruitingTreatmentRecurrent Osteosarcoma / Refractory Osteosarcoma1
1, 2RecruitingTreatmentRetinitis Pigmentosa (RP)1
1, 2SuspendedTreatmentColorectal Cancers1
1, 2TerminatedTreatmentBreast Cancer1
1, 2TerminatedTreatmentHepatitis C Viral Infection1
1, 2TerminatedTreatmentLung Cancers1
1, 2Unknown StatusTreatmentChronic Hepatitis C Virus (HCV) Infection1
1, 2Unknown StatusTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1, 2WithdrawnTreatmentBreast Cancer1
2Active Not RecruitingPreventionAutoantibody-Associated Heart Block / Congenital Heart Block / Neonatal Lupus1
2Active Not RecruitingPreventionNovel Coronavirus Infectious Disease (COVID-19)2
2Active Not RecruitingTreatmentBreast Cancer Stage IIB1
2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas2
2Active Not RecruitingTreatmentMultiple Sclerosis, Primary Progressive1
2Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / SARS-CoV 21
2Active Not RecruitingTreatmentProstate Cancer1
2CompletedTreatmentAdvanced Non Small Cell Lung Cancer / Non-Small Cell Lung Cancer Recurrent / Non-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentColorectal Cancers2
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentGlioblastomas1
2CompletedTreatmentHydroxychloroquine / IgA Patients1
2CompletedTreatmentInsulin Dependent Diabetes / Pancreatitis, Chronic1
2CompletedTreatmentLichen Planus, Oral1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2CompletedTreatmentOsteoarthritis of the Knee1
2CompletedTreatmentProstate Cancer1
2Enrolling by InvitationTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Respiratory Failure / Viral Pneumonia1
2Not Yet RecruitingPreventionNovel Coronavirus Infectious Disease (COVID-19)2
2Not Yet RecruitingTreatmentAnticoagulants / Antiphospholipid Syndrome in Pregnancy1
2Not Yet RecruitingTreatmentArthritis / Joint Pain1
2Not Yet RecruitingTreatmentCOVID / COVID - 19 / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
2Not Yet RecruitingTreatmentMalignancies, Hematologic / Novel Coronavirus Infectious Disease (COVID-19)1
2Not Yet RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)3
2Not Yet RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Pneumonitis, Interstitial1
2RecruitingPreventionCOVID 19 / Novel Coronavirus Infectious Disease (COVID-19)1
2RecruitingPreventionCoronavirus 19 / Coronavirus-19 / COVID / COVID - 19 / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
2RecruitingPreventionHealthy Volunteers / Rheumatoid Arthritis (RA) Prevention1
2RecruitingPreventionMalignancies / Novel Coronavirus Infectious Disease (COVID-19)1
2RecruitingPreventionSystemic Lupus Erythematosus (SLE)1
2RecruitingPreventionType1 Diabetes Mellitus1
2RecruitingTreatmentAntiphospholipid Syndrome (APS)1
2RecruitingTreatmentAortic Stiffness / Atherosclerosis / Cardiovascular Heart Disease / Chronic Kidney Disease (CKD) / Inflammatory Reaction1
2RecruitingTreatmentCOVID-19 Pneumonia / Novel Coronavirus Infectious Disease (COVID-19)1
2RecruitingTreatmentCOVID / COVID - 19 / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / SARS-CoV 2 / Viral Pneumonia1
2RecruitingTreatmentCOVID / COVID - 19 / Novel Coronavirus Infectious Disease (COVID-19)2
2RecruitingTreatmentCancer & COVID 19 / Novel Coronavirus Infectious Disease (COVID-19)1
2RecruitingTreatmentCancer, Advanced / Malignant Neoplasm of Pancreas1
2RecruitingTreatmentCerebrohepatorenal syndrome / Peroxisome Biogenesis Disorder (PBD)1
2RecruitingTreatmentCholangiocarcinoma Non-resectable / Cholangiocarcinoma, Perihilar / Cholangiocarcinomas / Extrahepatic Cholangiocarcinoma / Intrahepatic Cholangiocarcinoma1
2RecruitingTreatmentCoronavirus-19 / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
2RecruitingTreatmentDiabetes Mellitus Type 2 With Hyperglycemia1
2RecruitingTreatmentHepatocellular Cancer1
2RecruitingTreatmentHydroxychloroquine / Novel Coronavirus Infectious Disease (COVID-19) / Prophylaxis / Treatments1
2RecruitingTreatmentInfections, Coronavirus / Infectious Diseases / Novel Coronavirus Infectious Disease (COVID-19)1
2RecruitingTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / Viral Infections / Virus Diseases1
2RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)10
2RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Symptomatic COVID-19 Infection Laboratory-Confirmed1
2RecruitingTreatmentPorphyria Cutanea Tarda1
2RecruitingTreatmentRecurrent Prostate Cancer1
2RecruitingTreatmentSmall Cell Lung Cancer (SCLC)1
2SuspendedTreatmentChildren´s Interstitial Lung Disease / Diffuse Parenchymal Lung Diseases / Interstitial Lung Diseases (ILD)1
2SuspendedTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2TerminatedTreatmentArteriosclerosis / Cardiovascular Heart Disease / Chronic Renal Failure (CRF)1
2TerminatedTreatmentB-Cell Chronic Lymphocytic Leukemia1
2TerminatedTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2TerminatedTreatmentPancreatic Cancer Resectable1
2TerminatedTreatmentProstate Cancer1
2TerminatedTreatmentSarcomas1
2TerminatedTreatmentSystemic Lupus Erythematosus (SLE)1
2Unknown StatusPreventionFlu caused by Influenza1
2Unknown StatusTreatmentBreast Cancer1
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Unknown StatusTreatmentLeukemias1
2WithdrawnTreatmentAbortions spontaneous / Recurrent Pregnancy Losses1
2WithdrawnTreatmentHydroxychloroquine / Novel Coronavirus Infectious Disease (COVID-19) / Pregnant Women1
2, 3Active Not RecruitingTreatmentCOVID 19 / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
2, 3Active Not RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2, 3Enrolling by InvitationTreatmentCoVid 19 Positive / Novel Coronavirus Infectious Disease (COVID-19)1
2, 3Not Yet RecruitingPreventionHydroxychloroquine / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / Nursing Home / Prevention & Control1
2, 3Not Yet RecruitingPreventionNovel Coronavirus Infectious Disease (COVID-19)1
2, 3Not Yet RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS) / Acute Respiratory Distress Syndrome ARDS / Coronavirus (SARS-CoV) / COVID 19 / Novel Coronavirus Infectious Disease (COVID-19)1
2, 3Not Yet RecruitingTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
2, 3Not Yet RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)4
2, 3Not Yet RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / SARS-CoV 21
2, 3RecruitingPreventionInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
2, 3RecruitingPreventionInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / SARS (Severe Acute Respiratory Syndrome)1
2, 3RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)3
2, 3RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / SARS-CoV 21
2, 3RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Severe Acute Respiratory Syndrome1
2, 3SuspendedTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2, 3TerminatedTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / Viral Pneumonia1
3Active Not RecruitingPreventionNovel Coronavirus Infectious Disease (COVID-19)1
3Active Not RecruitingPreventionNovel Coronavirus Infectious Disease (COVID-19) / SARS-CoV 21
3Active Not RecruitingTreatmentCoronavirus (SARS-CoV) / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / Respiratory Infections, Acute1
3Active Not RecruitingTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
3CompletedSupportive CareGraft Versus Host Disease (GVHD)1
3CompletedTreatmentAcute Respiratory Distress Syndrome (ARDS) / Coronavirus (SARS-CoV) / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
3CompletedTreatmentAutoimmune Diseases / Dry Eye / Sjögren's Syndrome1
3CompletedTreatmentCutaneous Lupus Erythematosus-Systemic Lupus Erythematosus1
3CompletedTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / Pneumocystis Jirovecii Pneumonia1
3CompletedTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / Viral Pneumonia1
3CompletedTreatmentInsulin Resistance / Rheumatoid Arthritis1
3CompletedTreatmentOsteoarthritis (OA)1
3CompletedTreatmentPrimary Sjögren's Syndrome1
3CompletedTreatmentRheumatoid Arthritis7
3CompletedTreatmentSarcoidosis, Pulmonary1
3CompletedTreatmentSeronegative Spondyloarthropathies1
3Enrolling by InvitationPreventionInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / Pre-Exposure Prophylaxis / SARS-CoV 21
3Not Yet RecruitingPreventionCOVID 19 / Novel Coronavirus Infectious Disease (COVID-19)1
3Not Yet RecruitingPreventionCOVID / COVID - 19 / Novel Coronavirus Infectious Disease (COVID-19)1
3Not Yet RecruitingPreventionCOVID / COVID - 19 / Novel Coronavirus Infectious Disease (COVID-19) / Pulmonary Complications in Surgical Patients / Severe Acute Respiratory Syndrome1
3Not Yet RecruitingPreventionContact Person From COVID-19 Confirmed Patient / Novel Coronavirus Infectious Disease (COVID-19)1
3Not Yet RecruitingPreventionHealth Care Worker / Hydroxychloroquine / Novel Coronavirus Infectious Disease (COVID-19) / Prophylaxis1
3Not Yet RecruitingPreventionHealthcare Worker / Novel Coronavirus Infectious Disease (COVID-19) / Prophylaxis / Viral Infections1
3Not Yet RecruitingPreventionHydroxychloroquine Adverse Reaction / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
3Not Yet RecruitingPreventionInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
3Not Yet RecruitingPreventionNovel Coronavirus Infectious Disease (COVID-19)4
3Not Yet RecruitingTreatmentCOVID 19 / Novel Coronavirus Infectious Disease (COVID-19)1
3Not Yet RecruitingTreatmentCOVID-19 Pneumonia / Novel Coronavirus Infectious Disease (COVID-19)1
3Not Yet RecruitingTreatmentCovid-19 Infection / Novel Coronavirus Infectious Disease (COVID-19)1
3Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Novel Coronavirus Infectious Disease (COVID-19)1
3Not Yet RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)5
3Not Yet RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Respiratory Tract Infections (RTI)1
3RecruitingPreventionHealthcare Worker / Hydroxychloroquine / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / Prophylaxis / Wuhan Coronavirus1
3RecruitingPreventionHealthcare Worker / Hydroxychloroquine / Novel Coronavirus Infectious Disease (COVID-19) / Prophylaxis1
3RecruitingPreventionInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
3RecruitingPreventionInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / SARS-CoV 21
3RecruitingPreventionNovel Coronavirus Infectious Disease (COVID-19)4
3RecruitingPreventionNovel Coronavirus Infectious Disease (COVID-19) / Prevention of COVID-191
3RecruitingPreventionNovel Coronavirus Infectious Disease (COVID-19) / Severe Acute Respiratory Syndrome1
3RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS) / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
3RecruitingTreatmentCOVID - 19 / Novel Coronavirus Infectious Disease (COVID-19)1
3RecruitingTreatmentCOVID-19, Hydroxychloroquine Sulfate / Novel Coronavirus Infectious Disease (COVID-19)1
3RecruitingTreatmentCOVID / COVID - 19 / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / SARS-CoV 21
3RecruitingTreatmentCOVID / COVID - 19 / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / Viral Pneumonia1
3RecruitingTreatmentCOVID / COVID - 19 / Novel Coronavirus Infectious Disease (COVID-19)1
3RecruitingTreatmentCOVID / COVID - 19 / Novel Coronavirus Infectious Disease (COVID-19) / Pregnancy Related1
3RecruitingTreatmentCoronavirus (SARS-CoV) / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
3RecruitingTreatmentCoronavirus (SARS-CoV) / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / Respiratory Infections, Acute / Virus Diseases1
3RecruitingTreatmentFirst Trimester Abortion / Recurrent Miscarriages1
3RecruitingTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)2
3RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)6
3RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Pneumonia1
3RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Respiratory Distress Syndrome, Adult1
3RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Respiratory Failure1
3RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Severe Acute Respiratory Syndrome1
3RecruitingTreatmentRecurrent Pregnancy Losses1
3RecruitingTreatmentThrombocytopenia1
3SuspendedPreventionNovel Coronavirus Infectious Disease (COVID-19)1
3SuspendedTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
3SuspendedTreatmentNovel Coronavirus Infectious Disease (COVID-19)2
3TerminatedPreventionAntiphospholipid Syndrome1
3WithdrawnTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / Pulmonary Diseases / SARS (Severe Acute Respiratory Syndrome) / SARS-CoV 21
3WithdrawnTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Sars-CoV-2, Community-Acquired Pneumonia,COVID-191
4Active Not RecruitingTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
4Active Not RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
4CompletedBasic SciencePre-Diabetic1
4CompletedPreventionSystemic Lupus Erythematosus (SLE)1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Antirheumatic Agents / Cardiovascular Heart Disease / Hydroxychloroquine / Inflammatory Reaction / Myocardial Infarction1
4CompletedTreatmentAlopecia Areata (AA)1
4CompletedTreatmentAnkylosing Spondylitis (AS)1
4CompletedTreatmentBorrelia Infection / Lyme Disease1
4CompletedTreatmentImmune Thrombocytopenia1
4CompletedTreatmentPrimary IgA Nephropathy1
4CompletedTreatmentRheumatoid Arthritis6
4Enrolling by InvitationTreatmentNovel Coronavirus Infectious Disease (COVID-19)2
4Not Yet RecruitingPreventionBMI >30 kg/m22
4Not Yet RecruitingTreatmentAllergic granulomatous angiitis / ANCA Associated Vasculitis / Churg-Strauss Syndrome / Granulomatosis With Polyangiitis / Microscopic Polyangiitis1
4Not Yet RecruitingTreatmentAnkylosing Spondylitis (AS) / Spondyloarthritis1
4Not Yet RecruitingTreatmentAsymptomatic Infections / Novel Coronavirus Infectious Disease (COVID-19) / SARS-CoV2 Infection1
4Not Yet RecruitingTreatmentCOVID-19 Pneumonia / Novel Coronavirus Infectious Disease (COVID-19)1
4Not Yet RecruitingTreatmentCOVID / COVID - 19 / Novel Coronavirus Infectious Disease (COVID-19)1
4Not Yet RecruitingTreatmentInsufficient Response to Methotrexate / Rheumatoid Arthritis1
4Not Yet RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)3
4Not Yet RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Patients With COVID191
4Not Yet RecruitingTreatmentRheumatoid Arthritis1
4RecruitingPreventionAtrial Fibrillation (AF)1
4RecruitingTreatmentAsymptomatic Conditions / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
4RecruitingTreatmentCommunity-acquired Pneumonia, Influenza, COVID-191
4RecruitingTreatmentCoronary Artery Disease (CAD)1
4RecruitingTreatmentCutaneous Lupus / Juvenile SLE / Systemic Lupus Erythematosus (SLE)1
4RecruitingTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)2
4RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)2
4RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Symptomatic Condition1
4RecruitingTreatmentPrimary IgA Nephropathy1
4RecruitingTreatmentRheumatoid Arthritis3
4SuspendedTreatmentIndividuals Undergoing Cardiac and General Surgery1
4SuspendedTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
4TerminatedTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
Not AvailableActive Not RecruitingNot AvailableCOVID / COVID - 19 / Diarrhea / Novel Coronavirus Infectious Disease (COVID-19) / Pneumonia1
Not AvailableActive Not RecruitingPreventionAcute Respiratory Illnesses / Infections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
Not AvailableCompletedNot AvailableDry Mouth / Sjögren's Syndrome1
Not AvailableCompletedNot AvailableHydroxychloroquine / Ivermectin / Novel Coronavirus Infectious Disease (COVID-19)1
Not AvailableCompletedNot AvailableNovel Coronavirus Infectious Disease (COVID-19) / Rheumatoid Arthritis1
Not AvailableCompletedNot AvailablePatients With Systemic Lupus, or Skin Lupus / Systemic Lupus, Skin Lupus1
Not AvailableCompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedPreventionAntiphospholipid Syndrome1
Not AvailableCompletedTreatmentFavipiravir / Hydroxychloroquine / Kaletra / Lopinavir/Ritonavir / Novel Coronavirus Infectious Disease (COVID-19)1
Not AvailableCompletedTreatmentHashimoto's Thyroiditis1
Not AvailableCompletedTreatmentRheumatoid Arthritis2
Not AvailableNot Yet RecruitingNot AvailableAutoimmune Diseases1
Not AvailableNot Yet RecruitingNot AvailableLIPIN1 Deficiency1
Not AvailableNot Yet RecruitingPreventionHealthcare Workers / Novel Coronavirus Infectious Disease (COVID-19)1
Not AvailableNot Yet RecruitingPreventionInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
Not AvailableNot Yet RecruitingPreventionNovel Coronavirus Infectious Disease (COVID-19) / Post-exposure prophylaxis1
Not AvailableNot Yet RecruitingTreatmentCOVID-19 Patients / Novel Coronavirus Infectious Disease (COVID-19)1
Not AvailableNot Yet RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
Not AvailableNot Yet RecruitingTreatmentProlactinoma / Resistance, Disease1
Not AvailableRecruitingNot AvailableChildren / Immunosuppressive Treatment / Nephritis, Lupus / Steroid therapy1
Not AvailableRecruitingNot AvailableChloroquine Retinopathy / Proliferative Nephritis1
Not AvailableRecruitingNot AvailableInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19) / Pneumonitis1
Not AvailableRecruitingBasic ScienceInsulin Resistance1
Not AvailableRecruitingPreventionBehcet's Syndrome, Vascular Type / Study Focuses on the Long-term Effect of Hydroxychloroquine on the Prevention of Thrombotic Events of the Disease1
Not AvailableRecruitingPreventionHydroxychloroquine1
Not AvailableRecruitingSupportive CareCytokine Storm / Novel Coronavirus Infectious Disease (COVID-19) / Viral Pneumonia1
Not AvailableRecruitingSupportive CareNovel Coronavirus Infectious Disease (COVID-19) / Viral Pneumonia1
Not AvailableRecruitingTreatmentMetastatic NRAS Melanoma1
Not AvailableRecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)2
Not AvailableRecruitingTreatmentRecurrent Pregnancy Losses / Undifferentiated Connective Tissue Disease1
Not AvailableRecruitingTreatmentSurfactant Dysfunction1
Not AvailableRecruitingTreatmentSystemic Lupus Erythematosus (SLE)1
Not AvailableSuspendedOtherType 2 Diabetes Mellitus1
Not AvailableUnknown StatusTreatmentHashimoto's Thyroiditis1
Not AvailableWithdrawnPreventionNovel Coronavirus Infectious Disease (COVID-19)1
Not AvailableWithdrawnTreatmentChronic Urticaria1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Cadila Healthcare Ltd.
  • Cardinal Health
  • Caremark LLC
  • Comprehensive Consultant Services Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Ipca Laboratories Ltd.
  • Kaiser Foundation Hospital
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Professional Co.
  • Qualitest
  • Ranbaxy Laboratories
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Sanofi-Aventis Inc.
  • Southwood Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • United Research Laboratories Inc.
  • Watson Pharmaceuticals
  • West-Ward Pharmaceuticals
  • Winthrop Us
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
Tablet, film coatedEnteral200 mg/1
Tablet, film coatedOral200 mg/1
TabletOral
TabletOral200 mg/1
Prices
Unit descriptionCostUnit
Hydroxychloroquine sulf powder4.8USD g
Plaquenil 200 mg tablet3.14USD tablet
Hydroxychloroquine Sulfate 200 mg tablet1.28USD tablet
Hydroxychloroquine 200 mg tablet1.17USD tablet
Plaquenil Sulfate 200 mg Tablet0.66USD tablet
Apo-Hydroxyquine 200 mg Tablet0.35USD tablet
Mylan-Hydroxychloroquine 200 mg Tablet0.35USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)89-91U.S. Patent 2,546,658.
pKa9.67https://watermark.silverchair.com/dkg319.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAjkwggI1BgkqhkiG9w0BBwagggImMIICIgIBADCCAhsGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMINydGQAq9Ykq8ITSAgEQgIIB7KN6oy2fz4KHncExNPnuAQKYKCeJ2g-83oHmwqGXYloWqkUp7V_gNgs5P23NTTIZEIF_Tkfp9eBMlYlDl9YykaAzqA5UdihXdzBCxmyGaNX6adn_ov0d4hq2omPSpPVCW2dnKAaalROUpR1cm7FYyTXdiDdOn2LWFKDKmA7uuEFJ1ma7-5iCQKV86x7H1W4HOu7WEBQ_dgJPGZVH64g4KrC5SEw-ekFVVL4w40J_LDqVn5mR8sS57huG_Y7d4CWhtyc6Ko27hCp_nBEeaAo95nB4odR0zFGSEASSQZXGMaO2D8zHqk1wCTDVrTLJuyzjEFMel6T-k3yZQwIVdoNxcEY1bh8VwnEz0ugIrqAkimv5xjB9m8en6H1VhrEIhOVmW2GNJGF3No03F01vn3ePhKCXzgu7v3591flqV46i7r2ZnUYNDmE39IbXww4fqX_551wAPap6lMJ0fMsD_z2l3OzHUVis9cMUJm-nC3LtunwGotVRT4Xf8s7Y-La-5NGHI9KoQPfonM-jJcQ5C9sJFkQHasuB2_a3Inu_DFo-KMOAevqW4txzmR-QnwwV13kIHkcEP03vP0ByDKcsQM2mf2py_K2JxTENhiK0B2xc30W2W4fC1HbkrT-Jd9YStj2-A83nNX0_GMFSn4DT3A
Predicted Properties
PropertyValueSource
Water Solubility0.0261 mg/mLALOGPS
logP3.87ALOGPS
logP2.89ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area48.39 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity97.97 m3·mol-1ChemAxon
Polarizability38.3 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9892
Blood Brain Barrier+0.5602
Caco-2 permeable-0.5154
P-glycoprotein substrateSubstrate0.8348
P-glycoprotein inhibitor INon-inhibitor0.7297
P-glycoprotein inhibitor IIInhibitor0.5106
Renal organic cation transporterNon-inhibitor0.5742
CYP450 2C9 substrateNon-substrate0.8239
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateNon-substrate0.5384
CYP450 1A2 substrateNon-inhibitor0.5864
CYP450 2C9 inhibitorNon-inhibitor0.8457
CYP450 2D6 inhibitorNon-inhibitor0.6111
CYP450 2C19 inhibitorNon-inhibitor0.8782
CYP450 3A4 inhibitorNon-inhibitor0.6287
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7058
Ames testAMES toxic0.6907
CarcinogenicityNon-carcinogens0.837
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6348 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6798
hERG inhibition (predictor II)Inhibitor0.7173
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0f6t-3972000000-7c193125680c0c9e276f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 4-aminoquinolines. These are organic compounds containing an amino group attached to the 4-position of a quinoline ring system.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Aminoquinolines and derivatives
Direct Parent
4-aminoquinolines
Alternative Parents
Chloroquinolines / Secondary alkylarylamines / Aminopyridines and derivatives / Benzenoids / Aryl chlorides / Heteroaromatic compounds / Trialkylamines / 1,2-aminoalcohols / Azacyclic compounds / Primary alcohols
show 3 more
Substituents
Chloroquinoline / 4-aminoquinoline / Haloquinoline / Aminopyridine / Secondary aliphatic/aromatic amine / Aryl chloride / Aryl halide / Pyridine / Benzenoid / Heteroaromatic compound
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, organochlorine compound, secondary amino compound, primary alcohol, aminoquinoline (CHEBI:5801)

Targets

Kind
Nucleotide
Organism
Humans
Pharmacological action
Yes
Actions
Cross-linking/alkylation
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.
References
  1. Koranda FC: Antimalarials. J Am Acad Dermatol. 1981 Jun;4(6):650-5. [PubMed:6165744]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Transmembrane signaling receptor activity
Specific Function
Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR7 i...
Gene Name
TLR7
Uniprot ID
Q9NYK1
Uniprot Name
Toll-like receptor 7
Molecular Weight
120920.8 Da
References
  1. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L: TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35. [PubMed:18220957]
  2. Trevani AS, Chorny A, Salamone G, Vermeulen M, Gamberale R, Schettini J, Raiden S, Geffner J: Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol. 2003 Nov;33(11):3164-74. [PubMed:14579285]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Transmembrane signaling receptor activity
Specific Function
Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR9 i...
Gene Name
TLR9
Uniprot ID
Q9NR96
Uniprot Name
Toll-like receptor 9
Molecular Weight
115858.665 Da
References
  1. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L: TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35. [PubMed:18220957]
  2. Trevani AS, Chorny A, Salamone G, Vermeulen M, Gamberale R, Schettini J, Raiden S, Geffner J: Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol. 2003 Nov;33(11):3164-74. [PubMed:14579285]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Modulator
General Function
Zinc ion binding
Specific Function
Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-13 and dynorphin...
Gene Name
ACE2
Uniprot ID
Q9BYF1
Uniprot Name
Angiotensin-converting enzyme 2
Molecular Weight
92462.4 Da
References
  1. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2:69. doi: 10.1186/1743-422X-2-69. [PubMed:16115318]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Lim HS, Im JS, Cho JY, Bae KS, Klein TA, Yeom JS, Kim TS, Choi JS, Jang IJ, Park JW: Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75. doi: 10.1128/AAC.00339-08. Epub 2009 Feb 2. [PubMed:19188392]
  2. Collins KP, Jackson KM, Gustafson DL: Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. J Pharmacol Exp Ther. 2018 Jun;365(3):447-459. doi: 10.1124/jpet.117.245639. Epub 2018 Feb 8. [PubMed:29438998]
  3. Chary MA, Barbuto AF, Izadmehr S, Hayes BD, Burns MM: COVID-19: Therapeutics and Their Toxicities. J Med Toxicol. 2020 Apr 30. pii: 10.1007/s13181-020-00777-5. doi: 10.1007/s13181-020-00777-5. [PubMed:32356252]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Somer M, Kallio J, Pesonen U, Pyykko K, Huupponen R, Scheinin M: Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol. 2000 Jun;49(6):549-54. [PubMed:10848718]
  2. Chary MA, Barbuto AF, Izadmehr S, Hayes BD, Burns MM: COVID-19: Therapeutics and Their Toxicities. J Med Toxicol. 2020 Apr 30. pii: 10.1007/s13181-020-00777-5. doi: 10.1007/s13181-020-00777-5. [PubMed:32356252]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Chary MA, Barbuto AF, Izadmehr S, Hayes BD, Burns MM: COVID-19: Therapeutics and Their Toxicities. J Med Toxicol. 2020 Apr 30. pii: 10.1007/s13181-020-00777-5. doi: 10.1007/s13181-020-00777-5. [PubMed:32356252]

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Furst DE: Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996 Jun;5 Suppl 1:S11-5. [PubMed:8803904]
Kind
Protein group
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...

Components:
References
  1. Furst DE: Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996 Jun;5 Suppl 1:S11-5. [PubMed:8803904]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Crowe A, Ilett KF, Karunajeewa HA, Batty KT, Davis TM: Role of P glycoprotein in absorption of novel antimalarial drugs. Antimicrob Agents Chemother. 2006 Oct;50(10):3504-6. doi: 10.1128/AAC.00708-06. Epub 2006 Aug 17. [PubMed:16917012]
  2. Plaquenil (hydroxychloroquine sulfate) - Drug Summary [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Xu C, Zhu L, Chan T, Lu X, Shen W, Madigan MC, Gillies MC, Zhou F: Chloroquine and Hydroxychloroquine Are Novel Inhibitors of Human Organic Anion Transporting Polypeptide 1A2. J Pharm Sci. 2016 Feb;105(2):884-890. doi: 10.1002/jps.24663. Epub 2016 Jan 12. [PubMed:26429523]

Drug created on August 29, 2007 14:00 / Updated on July 11, 2020 00:05

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates